These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 25436495

  • 1. Retinoblastoma: evidence for postenucleation adjuvant chemotherapy.
    Kim JW.
    Int Ophthalmol Clin; 2015; 55(1):77-96. PubMed ID: 25436495
    [No Abstract] [Full Text] [Related]

  • 2. Retinoblastoma: approaching international standards for recommending chemotherapy (Commentary on Chantada et al., page 692).
    Meadows AT.
    Pediatr Blood Cancer; 2008 Mar; 50(3):521-2. PubMed ID: 18186114
    [No Abstract] [Full Text] [Related]

  • 3. [Retinoblastoma metastatic to the parotid gland: A case report].
    Zrafi WS, Kanoun Belajouza S, Mestiri S, Mokni M, Bouaouina N.
    J Fr Ophtalmol; 2018 Apr; 41(4):e141-e143. PubMed ID: 29655578
    [No Abstract] [Full Text] [Related]

  • 4. Retinoma underlying retinoblastoma revealed after tumor response to 1 cycle of chemotherapy.
    Dimaras H, Khetan V, Halliday W, Héon E, Chan HS, Gallie BL.
    Arch Ophthalmol; 2009 Aug; 127(8):1066-8. PubMed ID: 19667353
    [No Abstract] [Full Text] [Related]

  • 5. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group.
    Chantada GL, Doz F, Orjuela M, Qaddoumi I, Sitorus RS, Kepak T, Furmanchuk A, Castellanos M, Sharma T, Chevez-Barrios P, Rodriguez-Galindo C, International Retinoblastoma Staging Working Group.
    Pediatr Blood Cancer; 2008 Mar; 50(3):692-4. PubMed ID: 18059037
    [Abstract] [Full Text] [Related]

  • 6. [Current therapeutic management in retinoblastoma with invasion of the optic nerve--a case report].
    Gavriş M, Neamţu S, Gavriş S, Ghiţuică A.
    Oftalmologia; 1999 Mar; 46(1):69-71. PubMed ID: 10641091
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma.
    Chantada GL, Dunkel IJ, Antoneli CB, de Dávila MT, Arias V, Beaverson K, Fandiño AC, Chojniak M, Abramson DH.
    Pediatr Blood Cancer; 2007 Sep; 49(3):256-60. PubMed ID: 17029248
    [Abstract] [Full Text] [Related]

  • 8. A perspective on chemoreduction and focal therapy for retinoblastoma.
    Balasubramanya R, Pushker N, Bajaj MS, Ghose S, Rani A.
    Am J Ophthalmol; 2002 Oct; 134(4):633; author reply 633-4. PubMed ID: 12383837
    [No Abstract] [Full Text] [Related]

  • 9. Superselective intra-arterial chemotherapy for advanced retinoblastoma complicated by metastatic disease.
    Mathew AA, Sachdev N, Staffieri SE, McKenzie JD, Elder JE.
    J AAPOS; 2015 Feb; 19(1):72-4. PubMed ID: 25727592
    [Abstract] [Full Text] [Related]

  • 10. High Risk Retinoblastoma: Prevalence and Success of Treatment in Developing Countries.
    ElZomor H, Taha H, Aleieldin A, Nour R, Zaghloul MS, Fawzi M, Kamel A, Alfaar AS.
    Ophthalmic Genet; 2015 Feb; 36(3):287-9. PubMed ID: 25945688
    [No Abstract] [Full Text] [Related]

  • 11. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.
    Vajzovic LM, Murray TG, Aziz-Sultan MA, Schefler AC, Fernandes CE, Wolfe SC, Hess DJ, Dubovy SR.
    Arch Ophthalmol; 2010 Dec; 128(12):1619-23. PubMed ID: 21149791
    [No Abstract] [Full Text] [Related]

  • 12. A retrospective study on adjuvant chemotherapy in retinoblastoma: validation of the new recommendation against treatment for pT2a tumors based on the 8th AJCC classification.
    Alkatan HM, Almuzaini A, Helmi HA, Maktabi AM.
    BMC Ophthalmol; 2024 Jul 24; 24(1):309. PubMed ID: 39048946
    [Abstract] [Full Text] [Related]

  • 13. Treatment of overt extraocular retinoblastoma.
    Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E.
    Med Pediatr Oncol; 2003 Mar 24; 40(3):158-61. PubMed ID: 12518344
    [Abstract] [Full Text] [Related]

  • 14. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis.
    Zhao J, Dimaras H, Massey C, Xu X, Huang D, Li B, Chan HS, Gallie BL.
    J Clin Oncol; 2011 Mar 01; 29(7):845-51. PubMed ID: 21282531
    [Abstract] [Full Text] [Related]

  • 15. Chemoreduction in the management of retinoblastoma.
    Shields JA, Shields CL, Meadows AT.
    Am J Ophthalmol; 2005 Sep 01; 140(3):505-6. PubMed ID: 16139001
    [No Abstract] [Full Text] [Related]

  • 16. Histopathologic changes in retinoblastoma after chemoreduction.
    Dithmar S, Aabert TM, Grossniklaus HE.
    Retina; 2000 Sep 01; 20(1):33-6. PubMed ID: 10696744
    [Abstract] [Full Text] [Related]

  • 17. A 30-month prospective study on the treatment of retinoblastoma in the Gabriel Toure Teaching Hospital, Bamako, Mali.
    Boubacar T, Fatou S, Fousseyni T, Mariam S, Fatoumata DT, Toumani S, Abdoul-Aziz D, Marouf KM.
    Br J Ophthalmol; 2010 Apr 01; 94(4):467-9. PubMed ID: 19822911
    [Abstract] [Full Text] [Related]

  • 18. Advanced unilateral retinoblastoma: a case of sparing enucleation treatment failure.
    Valente P, De Ioris MA, Romanzo A, Cozza R, Natali G, Buzzonetti L.
    Can J Ophthalmol; 2016 Apr 01; 51(2):e40-3. PubMed ID: 27085272
    [No Abstract] [Full Text] [Related]

  • 19. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.
    Kaliki S, Shields CL, Shah SU, Eagle RC, Shields JA, Leahey A.
    Arch Ophthalmol; 2011 Nov 01; 129(11):1422-7. PubMed ID: 22084213
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.